|Articles|February 1, 2010
- Pharmaceutical Executive-02-01-2010
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - February 2010
Shire’s Second Act
Advertisement
Articles in this issue
over 16 years ago
A Sturdy Frameworkover 16 years ago
Vaccines and Valueover 16 years ago
Tearing Up the Rule Bookover 16 years ago
Assets for AdvantageAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
The Evolving Relationship Between FDA and Biotech
4
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
5